Access Statistics for Adrian Towse

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases 0 0 0 0 0 2 6 12
An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment 0 0 0 4 0 5 12 17
Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? 0 0 1 12 0 3 11 54
Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? 0 0 0 0 0 3 5 10
Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold 0 0 1 12 0 8 26 95
Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? 0 0 0 10 0 4 7 44
From Efficacy to Cost-Effectiveness 0 0 0 0 1 2 14 28
How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? 0 0 0 14 0 1 5 24
How Should the World Pay for a COVID-19 Vaccine? 0 0 1 33 1 5 14 126
Incentives for New Drugs to Tackle Anti-Microbial Resistance 0 0 0 46 0 4 8 133
Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? 0 0 0 24 1 6 20 112
Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward 0 0 1 26 0 5 13 123
Multi-indication Pricing: Pros, Cons and Applicability to the UK 0 0 0 19 2 5 17 173
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options 0 0 0 14 0 4 10 46
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement 0 0 0 101 1 3 15 225
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? 0 0 0 7 0 3 15 33
Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help? 0 0 0 3 1 4 10 34
Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry 0 0 0 5 0 1 14 43
The Future of Global Health Procurement: Issues around Pricing Transparency 0 0 2 19 1 5 20 59
The Market for Biosimilars: Evolution and Policy Options 0 0 0 4 1 5 10 27
The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? 0 0 0 6 1 4 10 41
Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds 0 0 0 0 0 2 8 13
Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context 0 1 1 57 0 11 22 190
Total Working Papers 0 1 7 416 10 95 292 1,662
30 registered items for which data could not be found

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare 0 0 0 6 0 5 13 67
Alternative funding models for medical innovation: the role of product development partnerships in product innovation for infectious diseases 0 0 0 2 2 3 9 13
Biosimilars: How Can Payers Get Long-Term Savings? 0 0 0 4 0 3 15 44
European Union Pharmaceutical Markets: A Case for Differential Pricing? 0 0 0 9 1 4 14 67
Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria 0 1 1 15 0 4 6 59
Genetic screening, health care and the insurance industry 0 0 0 1 1 1 6 24
Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al 0 0 0 1 0 2 9 15
If it ain't broke, don't price fix it: the OFT and the PPRS 0 0 0 58 0 1 8 197
Incentives for R&D for New Antimicrobial Drugs 0 0 1 47 0 3 6 159
Is disease management relevant in Europe: some evidence from the United Kingdom 0 0 0 16 1 6 9 52
Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? 0 0 0 15 0 2 12 50
Is rate of return pricing a useful approach when value-based pricing is not appropriate? 0 0 0 3 0 1 11 32
Medical negligence and the NHS: an economic analysis 0 0 0 1 0 4 5 167
Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value 0 0 0 0 2 2 11 11
Operationalizing Value-Based Pricing of Medicines 0 0 0 8 0 3 13 64
Orphan drugs policies: a suitable case for treatment 0 0 0 10 0 1 4 44
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement 0 0 1 8 0 2 8 61
Pricing combination products: not how but who? 0 0 0 0 0 3 8 8
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy 0 0 18 28 0 6 78 150
The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8 0 0 0 0 0 1 3 11
The desirability and feasibility of economic studies of drugs post-launch 0 0 0 32 0 0 6 105
Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation 0 0 0 3 0 2 8 39
Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context 0 1 1 23 3 6 14 160
Total Journal Articles 0 2 22 290 10 65 276 1,599

Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Biosimilars: How Much Entry and Price Competition Will Result? 0 0 0 8 1 4 13 52
Cost-Effectiveness Thresholds: Economic and ethical issues 0 0 7 146 2 4 24 581
Disease Management, the NHS and the Pharmaceutical Industry 0 0 0 4 1 1 8 40
Economic Post-Launch Studies: Matching the Desirable with the Feasible 0 0 0 1 0 1 9 45
Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS 1 1 2 8 1 1 10 43
Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? 0 0 0 2 1 2 10 51
Industrial Policy and the Pharmaceutical Industry 0 1 2 21 1 5 12 85
Influencing Prescribing in a Primary Care Led NHS 0 0 0 1 0 2 4 20
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options 0 0 0 5 0 0 7 53
Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty 0 0 1 18 0 1 8 107
The R&D Cost of a New Medicine 1 6 22 439 3 19 75 1,338
Value of the Pharmaceutical Industry to the UK Economy 0 0 1 22 1 4 15 83
Total Books 2 8 35 675 11 44 195 2,498
1 registered items for which data could not be found
logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-06-04